Request Your Free White Paper Now:

"Three Opportunities for Labs to Lead Improvements in Cancer Treatment"

As more targeted therapies become available, labs are required to test an expanding set of clinically actionable genomic targets. Next-generation sequencing (NGS) has enabled broad genetic testing, but its long turnaround times, high costs, and failure rates present new obstacles for labs to overcome.

This white paper from Agena Bioscience identifies three opportunities for labs to lead improvements in cancer treatment: expediting treatment by reducing testing times, lowering failure rates for better outcomes, and reducing testing costs to increase patient accessibility. By addressing these challenges, laboratories can significantly contribute to improving the overall quality of patient care, ensuring timely and successful treatment, and expanding access to molecular tumor profiling.

Offered Free by: Agena Bioscience
See All Resources from: Agena Bioscience